エピソード

  • S21:E2 – Individualizing Care Plans for Patients With AML

    S21:E2 – Individualizing Care Plans for Patients With AML
    2024/09/30

    In this episode, Individualizing Care Plans for Patients With AML, Dr. Amer Zeidan and Dr. Guillermo Garcia-Manero discuss how to incorporate evidence-based treatment plans for patients with AML who are receiving oral HMA maintenance therapy. Who are the best candidates for these therapies?

    Visit https://suiteweb.atpointofcare.com/#library/mds-aml/2646.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.
    続きを読む 一部表示
    24 分
  • S21:E1 – Improving Survival With HMA Maintenance Therapy in AML

    S21:E1 – Improving Survival With HMA Maintenance Therapy in AML
    2024/09/30

    In this episode, Improving Survival With HMA Therapy in AML, Dr. Amer Zeidan and Dr. Guillermo Garcia-Manero discuss the latest clinical trial evidence for using hypomethylating agents as maintenance therapy for AML patients as well as which patients will benefit most from these therapies.

    Visit https://suiteweb.atpointofcare.com/#library/mds-aml/2646.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.
    続きを読む 一部表示
    42 分
  • S21:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies

    S21:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies
    2024/01/29

    In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar. Visit https://suitehome.atpointofcare.com/library/2606.13/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.
    続きを読む 一部表示
    23 分
  • S20:E2 – Latest Clinical Trial Data of Emerging, TROP2-Targeting Agents in Advanced NSCLC

    S20:E2 – Latest Clinical Trial Data of Emerging, TROP2-Targeting Agents in Advanced NSCLC
    2024/01/29

    In this episode our faculty look at some of the clinical data on anti-Trop-2 treatments and why they may be heralding an exciting future for the treatment of non-small cell lung cancer. Visit https://suitehome.atpointofcare.com/library/2606.12/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.
    続きを読む 一部表示
    31 分
  • S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC)

    S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC)
    2024/01/29

    In this episode, Clinical Implications of Trophoblast-Cell Surface Antigen 2 in Non-Small Cell Lung Cancer, Dr. Justin Gainor and Dr. Helena Yu discusses the current diagnosis and treatment of non-small cell lung cancer as well as a new ADC target, trophoblast cell-surface antigen 2 or Trop2.

    Visit https://suiteweb.atpointofcare.com/#library/nsclc/2606.11/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.
    続きを読む 一部表示
    26 分
  • S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer

    S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer
    2023/12/29

    Our faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them.

    Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    続きを読む 一部表示
    26 分
  • S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer

    S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer
    2023/12/29

    In this episode our faculty take a look at the clinical trial data on HER3-directed therapies for breast and lung cancer.

    Visit www.morningcommutepodcast.com/HER3Agnostic2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    続きを読む 一部表示
    31 分
  • S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?

    S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?
    2023/12/29

    In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar.

    Visit www.morningcommutepodcast.com/HER3Agnostic1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    続きを読む 一部表示
    26 分